Back to Browse Journals » Vascular Health and Risk Management » Volume 8

Microencapsulated conjugated linoleic acid associated with hypocaloric diet reduces body fat in sedentary women with metabolic syndrome

Authors Carvalho RF, Uehara SK, Rosa G

Received 27 August 2012

Accepted for publication 9 October 2012

Published 13 December 2012 Volume 2012:8 Pages 661—667


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Roberta F Carvalho,1 Sofia K Uehara,2 Glorimar Rosa1,2

1Medicine Department, Federal University of Rio de Janeiro, Brazil; 2Nutrition and Dietetic Department, Josué de Castro Institute of Nutrition, Federal University of Rio de Janeiro, Brazil

Background: Animal studies have suggested beneficial effects of conjugated linoleic acid (CLA) in reducing body fat mass and improvement in the serum lipid profile and glycemia. However, these effects are controversial in humans. The purpose of this study was to investigate the effects of microencapsulated CLA supplementation on body composition, body mass index, waist circumference, and blood pressure in sedentary women with metabolic syndrome.
Methods: This study was a placebo-controlled and randomized clinical trial. Fourteen women diagnosed with metabolic syndrome received light strawberry jam enriched or not with microencapsulated CLA (3 g/day) as a mixture of 38.57% cis-9, trans-11, and 39.76% trans-10, cis-12 CLA isomers associated with a hypocaloric diet for 90 days. The subjects were monitored to assess variables associated with the metabolic syndrome, in addition to assessing adherence with the intervention.
Results: There were no significant effects of microencapsulated CLA on the lipid profile or blood pressure. Mean plasma insulin concentrations were significantly lower in women supplemented with microencapsulated CLA (Δ T90 – T0 = −12.87 ± 4.26 µU/mL, P = 0.02). Microencapsulated CLA supplementation did not alter the waist circumference, but there was a reduction in body fat mass detected after 30 days (Δ = −2.68% ± 0.82%, P = 0.02), which was maintained until the 90-day intervention period (Δ = −3.32% ± 1.41%, P = 0.02) in the microencapsulated CLA group. The placebo group showed this effect only after 90 days (Δ = −1.97% ± 0.60%, P = 0.02), but had a reduced waist circumference (Δ T90 – T0 = −4.25 ± 1.31 cm, P = 0.03).
Conclusion: Supplementation with mixed-isomer microencapsulated CLA may have a favorable effect on glycemic control and body fat mass loss at an earlier time in sedentary women with metabolic syndrome, although there were no effects on lipid profile and blood pressure.

Keywords: conjugated linoleic acid, metabolic syndrome, body composition, cardiovascular disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Readers of this article also read:

Lipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA Registry

Schaefer JR, Gitt AK, Sonntag F, Weizel A, Jannowitz C, Karmann B, Pittrow D, Bestehorn K

Vascular Health and Risk Management 2013, 9:71-80

Published Date: 21 February 2013

Cerebral blood flow in Alzheimer’s disease

Roher AE, Debbins JP, Malek-Ahmadi M, Chen K, Pipe JG, Maze S, Belden C, Maarouf CL, Thiyyagura P, Mo H, Hunter JM, Kokjohn TA, Walker DG, Kruchowsky JC, Belohlavek M, Sabbagh MN, Beach TG

Vascular Health and Risk Management 2012, 8:599-611

Published Date: 23 October 2012

Helicobacter pylori infection is identified as a cardiovascular risk factor in Central Africans

Longo-Mbenza B, Nsenga JN, Mokondjimobe E, Gombet T, Assori IN, Ibara JR, Ellenga-Mbolla B, Vangu DN, Fuele SM

Vascular Health and Risk Management 2012, 8:455-461

Published Date: 15 August 2012

Percutaneous mechanical thrombectomy for treatment of acute femoropopliteal bypass occlusion

Lichtenberg M, Käunicke M, Hailer B

Vascular Health and Risk Management 2012, 8:283-289

Published Date: 4 May 2012

Lack of a relationship between circulating gamma-glutamyltransferase levels and carotid intima media thickness in hypertensive and diabetic patients

Nuti M, Spontoni P, Grigoratos C, Dell'Omo G, Balbarini A, Pedrinelli R

Vascular Health and Risk Management 2012, 8:275-281

Published Date: 1 May 2012

Mixed dyslipidemias in primary care patients in France

Laforest L, Ambegaonkar BM, Souchet T, Sazonov V, Van Ganse E

Vascular Health and Risk Management 2012, 8:247-254

Published Date: 19 April 2012

Effects of a 6-month exercise program pilot study on walking economy, peak physiological characteristics, and walking performance in patients with peripheral arterial disease

Crowther RG, Leicht AS, Spinks WL, Sangla K, Quigley F, Golledge J

Vascular Health and Risk Management 2012, 8:225-232

Published Date: 17 April 2012

Absorbable stent: focus on clinical applications and benefits

Gonzalo N, Macaya C

Vascular Health and Risk Management 2012, 8:125-132

Published Date: 29 February 2012

Role of ICAM-1 and E-selectin gene polymorphisms in pathogenesis of PAOD in Egyptian patients

Olfat Shaker, Amr Zahra, Ahmed Sayed, et al

Vascular Health and Risk Management 2010, 6:9-15

Published Date: 24 December 2009